A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
Public ClinicalTrials.gov record NCT05211323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab and atezolizumab with chemotherapy may kill more tumor cells in patients liver cancer than chemotherapy and atezolizumab.
Study identification
- NCT ID
- NCT05211323
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Biological
- Bevacizumab Biological
- Biospecimen Collection Procedure
- Cisplatin Drug
- Computed Tomography Procedure
- Conventional Magnetic Resonance Imaging Procedure
- Gemcitabine Hydrochloride Drug
Biological · Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2022 (Actual)
- Primary completion
- Jan 20, 2026 (Actual)
- Completion
- Aug 10, 2027 (Estimated)
- Last update posted
- Aug 13, 2026
2022 – 2027
United States locations
- U.S. sites
- 37
- U.S. states
- 8
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sutter Auburn Faith Hospital | Auburn | California | 95602 | — |
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | 94704 | — |
| Palo Alto Medical Foundation-Fremont | Fremont | California | 94538 | — |
| Memorial Medical Center | Modesto | California | 95355 | — |
| Palo Alto Medical Foundation-Camino Division | Mountain View | California | 94040 | — |
| Palo Alto Medical Foundation Health Care | Palo Alto | California | 94301 | — |
| Sutter Roseville Medical Center | Roseville | California | 95661 | — |
| Sutter Medical Center Sacramento | Sacramento | California | 95816 | — |
| California Pacific Medical Center-Pacific Campus | San Francisco | California | 94115 | — |
| Palo Alto Medical Foundation-Santa Cruz | Santa Cruz | California | 95065 | — |
| Palo Alto Medical Foundation-Sunnyvale | Sunnyvale | California | 94086 | — |
| Sutter Solano Medical Center/Cancer Center | Vallejo | California | 94589 | — |
| Carle at The Riverfront | Danville | Illinois | 61832 | — |
| Carle Physician Group-Effingham | Effingham | Illinois | 62401 | — |
| Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois | 61938 | — |
| Carle Cancer Center | Urbana | Illinois | 61801 | — |
| The Carle Foundation Hospital | Urbana | Illinois | 61801 | — |
| Memorial Hospital of South Bend | South Bend | Indiana | 46601 | — |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny | Iowa | 50023 | — |
| Iowa Methodist Medical Center | Des Moines | Iowa | 50309 | — |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines | Iowa | 50309 | — |
| Mercy Medical Center - Des Moines | Des Moines | Iowa | 50314 | — |
| Miami Valley Hospital South | Centerville | Ohio | 45459 | — |
| Miami Valley Hospital | Dayton | Ohio | 45409 | — |
| Premier Blood and Cancer Center | Dayton | Ohio | 45409 | — |
| Miami Valley Hospital North | Dayton | Ohio | 45415 | — |
| Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio | 45005-1066 | — |
| Miami Valley Cancer Care and Infusion | Greenville | Ohio | 45331 | — |
| Upper Valley Medical Center | Troy | Ohio | 45373 | — |
| Parkland Memorial Hospital | Dallas | Texas | 75235 | — |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | 75390 | — |
| UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth | Texas | 76104 | — |
| UT Southwestern Clinical Center at Richardson/Plano | Richardson | Texas | 75080 | — |
| VCU Massey Cancer Center at Stony Point | Richmond | Virginia | 23235 | — |
| VCU Massey Comprehensive Cancer Center | Richmond | Virginia | 23298 | — |
| Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | 54701 | — |
| Marshfield Medical Center - Minocqua | Minocqua | Wisconsin | 54548 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05211323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05211323 live on ClinicalTrials.gov.